Six-Month Results of the NEVO RES-ELUTION I (NEVO RES-I) TrialClinical Perspective

Background— Drug-eluting stents reduce restenosis and reintervention rates but are complicated by stent thrombosis, which may be related to polymer coating. The NEVO sirolimus-eluting coronary stent (NEVO SES) is designed to improve long-term percutaneous coronary intervention safety by combining sirolimus release from reservoirs with bioabsorbable polymer to reduce spatial and temporal polymer exposure. Methods and Results— NEVO ResElution-I was a prospective randomized study in 394 patients with coronary artery disease comparing the NEVO SES with the TAXUS Liberte paclitaxel-eluting coronary stent (TAXUS Liberte PES) stent. The primary end point was in-stent angiographic late loss at 6 months. Six months after percutaneous coronary intervention (PCI), the primary end point favored NEVO SES (0.13±0.31 mm versus 0.36±0.48 mm, P <0.001 for noninferiority and superiority). The study was not powered for clinical end points and showed no significant difference for NEVO SES versus TAXUS Liberte PES: death: 0.5 versus 1.6%, P =0.36; myocardial infarction: 2.0 versus 2.6%, P =0.75; target lesion revascularization: 1.5 versus 3.2%, P =0.33; major adverse cardiac events: 4.0 versus 7.4%, P =0.19. No stent thrombosis was observed with NEVO SES, whereas 2 cases occurred in TAXUS Liberte PES. Intravascular ultrasound showed lower percent volume obstruction for NEVO SES (5.5±11% versus 11.5±9.7%, P =0.016). Conclusions— This trial proved the superiority of NEVO SES over TAXUS Liberte PES for the primary angiographic end point of in-stent late loss. No stent thrombosis occurred in the NEVO SES group. Clinical Trial Registration— URL: . Unique identifier: [NCT00606333][1]. [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00606333&atom=%2Fcirccvint%2F3%2F6%2F556.atom